Anascorp (centruroides (scorpion) polyvalent antivenom)
Intravenous Vial (EA)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Centruroides (scorpion) immune F(ab')2 (equine) is a polyvalent antivenom preparation of equine immunoglobulin G (IgG) F(ab')2 fragments capable of binding and neutralizing venom toxins of Centruroides scorpions.
Centruroides (scorpion) immune F(ab')2 (equine) is a polyvalent antivenom preparation of venom-specific F(ab')2 fragments of equine immunoglobulin G (IgG) that bind and neutralize Centruroides venom toxins, facilitating redistribution of the venom away from target tissues and elimination from the body. The antivenom is prepared from the plasma of horses immunized with the venom of Centruroides noxius, C. limpidus limpidus, C. limpidus tecomanus, and C. suffusus suffusus. Although C. sculpturatus venom is not used in the preparation of Centruroides (scorpion) immune F(ab')2 (equine), in vitro studies demonstrate similar binding affinities and a high degree of cross-reactivity among the venoms of the various Centruroides species, including C. sculpturatus.
Centruroides (scorpion) immune F(ab')2 (equine) commercially available in the US is a lyophilized preparation that contains not less than 85% F(ab')2, not more than 7% F(ab), and less than 5% intact immunoglobin. The antivenom is stabilized with sodium chloride, sucrose, and glycine, and may contain trace amounts of pepsin, cresol, borates, and sulfates from the manufacturing process. Several steps in the manufacturing process (pepsin digestion, ammonium sulfate precipitation/heat treatment, nanofiltration) reduce the risk of transmission of viruses. (See Risk of Transmissible Infectious Agents under Cautions: Warnings/Precautions.)
Centruroides (scorpion) immune F(ab')2 (equine) is standardized by its ability to neutralize Centruroides scorpion venom in mice (mouse LD50 neutralizing units). Each commercially available vial will neutralize at least 150 mouse LD50 units of Centruroides venom. Following IV administration in healthy (nonenvenomed) adults, Centruroides (scorpion) immune F(ab')2 (equine) has a half-life of approximately 6.6 days.
Additional study is needed to determine the pharmacokinetics of the antivenom in patients with scorpion envenomation.
Generic name: centruroides (scorpion) polyvalent antivenom
Therapeutic class: Biologicals
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Anascorp
Indications
The following indications are listed for Anascorp:
- Poisoning Due To Scorpion Venom
Also known as: Scorpion Envenomation.
Dosing
Dosage of Centruroides (scorpion) immune F(ab')2 (equine) is expressed in terms of the number of vials of the antivenom.
The recommended initial dose of Centruroides (scorpion) immune F(ab')2 (equine) in adults and children is 3 vials. Patients should be monitored for resolution of signs of envenomation during and for up to 1 hour after the IV infusion. Additional 1-vial doses may be administered every 30-60 minutes as needed.
Centruroides (scorpion) immune F(ab')2 (equine) is administered by IV infusion.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
Formal drug interaction studies have not been performed with Centruroides (scorpion) immune F(ab')2 (equine).
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
The manufacturer states there are no contraindications.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
- No disease contraindications
Adverse reactions
Adverse effects reported in 2% or more of patients receiving Centruroides (scorpion) immune F(ab')2 (equine) include vomiting, pyrexia, rash, nausea, and pruritus.
Rare or Very Rare
- Anaphylaxis
- Serum sickness
Rare or Very Rare
- Skin rash
- Urticaria
Precautions
No enhanced messaging available.
Efficacy and safety of Centruroides (scorpion) immune F(ab')2 (equine) in pediatric patients are comparable to that in adults. In clinical trials of Centruroides (scorpion) immune F(ab')2 (equine), 78% of patients were children ranging from younger than 1 month to 18 years of age.
Category C. (See Users Guide.)
It is not known whether Centruroides (scorpion) immune F(ab')2 (equine) is distributed into milk. Caution is advised if the antivenom is administered in nursing women.
Efficacy and safety of Centruroides (scorpion) immune F(ab')2 (equine) have not been studied specifically in geriatric patients; however, 77 patients in clinical trials were older than 65 years of age and efficacy and safety in these adults were considered comparable to that of the overall patient population.
ICD codes
| Code | Type | Description |
|---|---|---|
| Poisoning due to scorpion venom | ||
| T63.2x1A | ICD10CM | Toxic effect of venom of scorpion, accidental (unintentional), initial encounter |
| T63.2x2A | ICD10CM | Toxic effect of venom of scorpion, intentional self-harm, initial encounter |
| T63.2x3A | ICD10CM | Toxic effect of venom of scorpion, assault, initial encounter |
| T63.2x4A | ICD10CM | Toxic effect of venom of scorpion, undetermined, initial encounter |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.